Brittany Harris FNP-C

A new infographic from the Sleep Medicine Network describes updated recommendations for the treatment of restless legs syndrome. Learn more: https://hubs.la/Q0488CzM0

Among adults with , single-day inhaled GH001 resulted in rapid, significant symptom reduction and remission vs placebo, with no severe adverse events and sustained effects over 6 months.

https://ja.ma/4d4ucpW

The 2026 ACC/AHA Dyslipidemia
Guidelines

These new updates bring major shifts in risk assessment, novel lipid markers, and cholesterol targets.

Here are the most salient features you need to know.👇
https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016

A prospective single-cohort study published in the International Journal of Environmental Research and Public Health (2023) investigated the efficacy of oral N-acetylcysteine (NAC) in women with endometriosis. The study included 120 patients aged 18–45 years who received NAC 600 mg three times daily for three consecutive days per week over a three-month period. Results showed significant improvements in endometriosis-related pain symptoms, including dysmenorrhea, dyspareunia, and chronic pelvic pain, as measured by Visual Analog Scale (VAS) scores. The use of NSAIDs significantly decreased, and there was a meaningful reduction in the average size of ovarian endometriomas as well as serum Ca125 levels, suggesting reduced inflammatory activity.

Additionally, among the 52 women who expressed a desire for pregnancy, 39 achieved spontaneous conception within six months of initiating NAC therapy, and 6 conceived through assisted reproductive techniques. These findings indicate that NAC’s antioxidant and anti-inflammatory properties may contribute to improved fertility outcomes, possibly by enhancing oocyte quality and reducing oxidative stress. Overall, the study suggests that NAC may serve as a safe and effective non-hormonal therapeutic option for managing pain, reducing lesion size, lowering Ca125 levels, and supporting fertility in women with endometriosis.

PMCID: PMC10048621 PMID: 36981595

According to a randomized, double-blind, placebo-controlled trial published in Arthritis & Rheumatism, researchers evaluated N-acetylcysteine (NAC) in patients with systemic lupus erythematosus (SLE). Participants received either placebo or NAC at doses of 1.2 g/day or 2.4 g/day for three months. The 2,400 mg/day group showed the most significant improvement, with SLE Disease Activity Index (SLEDAI) scores dropping by nearly 40% compared to baseline, indicating a meaningful reduction in overall disease activity.

The study found that NAC works mechanistically by inhibiting mTOR activation in T cells, a pathway known to drive immune overactivation in lupus. By restoring intracellular glutathione levels and reducing oxidative stress, NAC suppressed abnormal immune signaling, improved regulatory T-cell function, and reduced autoantibody production. The benefits were observed within 12 weeks, with the higher dose producing the strongest clinical and immunological effects.

PMCID: PMC3411859 NIHMSID: NIHMS371296 PMID: 22549432

Intravenous nicotinamide adenine dinucleotide (NAD⁺) has emerged as a potential novel therapy for patients with ischemic heart failure, a condition characterized by reduced left ventricular ejection fraction and impaired cardiac energy metabolism.

Because NAD⁺ plays a central role in cellular energy production and redox balance, restoring its levels may help improve myocardial function in patients with ischemic cardiomyopathy. Recent clinical research suggests that short-term intravenous NAD⁺ administration can significantly improve heart pumping function within one month, with additional favorable trends in biomarkers and clinical outcomes.

Although further large-scale studies are needed, these findings highlight NAD⁺ repletion as a promising strategy for enhancing cardiac performance in patients with ischemic heart failure.

PMID: 40954388

https://journals.sagepub.com/doi/abs/10.1177/13872877251389608?_gl=1*1kkp9zk*_up*MQ..*_ga*NzI1NzAyMzczLjE3NzA2Nzg1MzM.*_ga_60R758KFDG*czE3NzA2Nzg1MzMkbzEkZzEkdDE3NzA2Nzg1NDUkajQ4JGwwJGgzNzM5MzA4MTE.

I tell yall!

According to the Chinese Coronary Secondary Prevention Study, published in the American Journal of Cardiology (2008), patients with a prior myocardial infarction who were treated with Xuezhikang (a standardized red yeast rice extract) experienced fewer non-fatal heart attacks, fewer deaths from coronary heart disease, and fewer major coronary events compared with placebo over a 4.5-year follow-up period. According to this study, major coronary events were specifically defined as non-fatal myocardial infarction, death from coronary heart disease, and the need for coronary revascularization procedures, making it one of the few large randomized trials to show a reduction in hard cardiovascular outcomes with a nutraceutical intervention.

In a significant shift for mental health care, the U.S. Food and Drug Administration has approved the first anxiety treatment designed to work through the gut–brain connection. This approach moves away from medications that act only on brain receptors and chemistry.

The treatment belongs to a class known as psychobiotics—beneficial bacteria that influence mood and stress by reshaping the gut microbiome. Research shows gut microbes help regulate inflammation, produce neurotransmitters such as serotonin and GABA, and communicate with the brain via the vagus nerve.

Clinical studies supporting approval reported reduced anxiety symptoms, improved emotional regulation, and better sleep. Scientists say the findings confirm the gut’s central role in mental health, opening the door to more biologically integrated anxiety treatments.

Source: U.S. Food and Drug Administration; Nature Reviews Gastroenterology & Hepatology; National Institute of Mental Health
Shared for informational/Educational purpose only